CNS Pharmaceuticals, Inc. Payments of Stock Issuance Costs
CNS Pharmaceuticals, Inc. (CNSP) reported Payments of Stock Issuance Costs of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-08-12
- CNS Pharmaceuticals, Inc. payments of stock issuance costs for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- CNS Pharmaceuticals, Inc. payments of stock issuance costs for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- CNS Pharmaceuticals, Inc. payments of stock issuance costs for the quarter ending 2025-12-31 was $0.00.
- CNS Pharmaceuticals, Inc. payments of stock issuance costs for the quarter ending 2025-09-30 was $1.04K.
- CNS Pharmaceuticals, Inc. payments of stock issuance costs for fiscal 2025 was $2.04K.
- CNS Pharmaceuticals, Inc. payments of stock issuance costs for fiscal 2024 was $0.00.
- CNS Pharmaceuticals, Inc. payments of stock issuance costs for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- CNS Pharmaceuticals, Inc. payments of stock issuance costs for fiscal 2018 was $21.00K.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 6 month as first filed | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 | $0.00 derived: sum of 3 quarters · filed 2026-08-12 | $1.04K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-14 | $0.00 derived: sum of 2 quarters · filed 2026-05-14 | $1.04K derived: sum of 3 quarters · filed 2026-05-14 | $1.49K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.04K derived: sum of 2 quarters · filed 2026-03-31 | $1.49K derived: sum of 3 quarters · filed 2026-08-12 | $2.04K 10-K · filed 2026-03-31 | |
| 2025-09-30 | $1.04K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.49K derived: sum of 2 quarters · filed 2026-08-12 | $2.04K 10-Q · filed 2025-11-14 | $2.04K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | $443.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $1.00K 10-Q · filed 2026-08-12 | $557.00 10-Q · filed 2025-08-14 | $1.00K derived: sum of 3 quarters · filed 2026-08-12 | $1.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $557.00 10-Q · filed 2026-05-14 | $557.00 derived: sum of 2 quarters · filed 2026-05-14 | $557.00 derived: sum of 3 quarters · filed 2026-05-14 | $557.00 derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $0.00 derived: sum of 2 quarters · filed 2026-03-31 | $0.00 derived: sum of 3 quarters · filed 2026-03-31 | $0.00 10-K · filed 2026-03-31 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2025-11-14 | $0.00 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-15 | ||||
| 2019-12-31 | $0.00 10-K · filed 2020-03-12 | ||||
| 2018-12-31 | $21.00K 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |